Re: Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

Sheng Yu, MD

doi:10.1093/jnci/djag212

Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates

2026-07-07

0

PRE

AI

Z

Zunairah Shah, MD

L

Lan Lei, MD

R

Rahul Thakur, MD

A

Ajinkya Buradkar, MD

M

Malak Alharbi, MD

M

Mulham Ombada, MD

S

Song Yao, PhD

A

Alfredo Chua

H

Han Yu, PhD

S

Sunil Badve, MD

T

Thaer Khoury, MD

A

Anant Madabhushi, PhD

U

Ujjwal Baid, PhD

K

Kevin Kalinsky, MD

S

Sheheryar Kabraji, BMBCh

S

Shipra Gandhi, MD *

DOI：10.1093/jnci/djag223

Original

Original request for help

Save

Abstract

En 中文

Antibody–drug conjugates (ADCs) have substantially improved outcomes for patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Whether these survival gains have translated equitably across racial and ethnic groups remains unclear despite persistent disparities in breast cancer outcomes.

Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates

Abstract

Journal

Organization

Cited Papers

Citing Papers